论文部分内容阅读
本文报道用生长抑素八肽类似物(Sandostatin, SMS201—995)治疗10例活动性肢端肥大症20.3±7.5个月的结果。治疗剂量为300～1500μg/d,分3次,每8小时皮下注射1次。结合临床及血清GH及SMC值评定,在用药期间,2例控制正常,4例显效,3例有效,1例无效。5例新诊断患者用药6个月后1例的微腺瘤消失,4例大腺瘤高度由12.4±4.9mm降至9.8±4.4mm。8例患者有短暂的胃肠道反应,8例胆囊收缩功能减弱,4例糖耐量变坏。指出SMS201-995对肢端肥大症有疗效,但其治疗价值尚待进一步研究。
This article reports the results of 10 cases of active acromegaly 20.3 ± 7.5 months treated with the somatostatin octapeptide analogue (Sandostatin, SMS 201-995). Treatment dose of 300 ~ 1500μg / d, 3 times, every 8 hours subcutaneously once. Combined with clinical and serum GH and SMC value assessment, during the medication, 2 cases of normal control, 4 cases markedly effective in 3 cases, 1 case ineffective. In 5 newly diagnosed patients, one case of microadenomas disappeared after 6 months of treatment, and the height of 4 cases of large adenomas decreased from 12.4 ± 4.9mm to 9.8 ± 4.4mm. 8 patients had a transient gastrointestinal reaction, 8 patients with impaired cholecystokinin, 4 patients with impaired glucose tolerance. Pointed out that SMS201-995 is effective on acromegaly, but its therapeutic value remains to be further studied.